Tag Archives: RSV

Matthew 24:12-34 The End of the World – A Poem by Jesus

In the Olivet Discourse, Jesus creates a poem about the end of the world. The poem is based on a rhyme between the Hebrew words “The End” and “Summer or Summer Fruit.” Jesus is expounding on a poem in Amos 8:1-2 that uses the same rhyme and the same theme. However, he adds an additional rhyme that involves “Wickedness,” “Saved,” “Gates,” and “Shall be done.” The words “Saved” and “Wickedness” use many of the same letters but the letters are prioritized differently. Almost as if they were symbolizing that it is how everything is prioritized that is the difference between “Saved” and “Wickedness.”

“The End” (קץ)

“Summer Fruit” (קיץ)

“Wickedness” (הרשעות)

“Saved” (יושע)

“Gates” (לשערים)

“Shall be done” (יהיו עשוים)

8:1 “Thus the Lord GOD showed me: behold, a basket of summer fruit {“Summer Fruit” (קיץ)}. 2 And he said, “Amos, what do you see?” And I said, “A basket of summer fruit {“Summer Fruit” (קיץ)}.” Then the LORD said to me, “The end {“The End” (קץ)} has come upon my people Israel; I will never again pass by them.” [Amos 8:1-2 RSV]

24:12 And because wickedness {“Wickedness” (הרשעות)} will increase, the love of most will grow cold. 13 But he who endures to the end {“The End” (קץ)} will be saved {“Saved” (יושע)}. 14 And this gospel of the kingdom will be preached in the whole world as a testimony to all nations, and then the end {“The End” (קץ)} will come.

24:32 “Now learn this lesson from the fig tree: as soon as its branch becomes tender and puts forth its leaves, you know that summer {Summer” (קיץ) or “Summer Fruit” (קיץ)} is near. 33 So also, when you see all these things, you know that it is near, right at the door {“Gates” (לשערים)}. 34 Truly, I tell you that this generation will by no means pass away till all these things take place {<span style="font-family:'book …read more

Source: Worthy Christian Forums

Alnylam to Webcast Presentation at Barclays Global Healthcare Conference

By Business Wirevia The Motley Fool

Filed under:

Alnylam to Webcast Presentation at Barclays Global Healthcare Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Tuesday, March 12, 2013 at 10:15 a.m. ET at the Loews Miami Hotel in Miami, Florida.

A live audio webcast of the presentation will be available on the News & Investors section of the company’s website, www.alnylam.com. A replay of the presentation will be available on the Alnylam website within 48 hours after the event.

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR), ALN-AT3 for the treatment of hemophilia and rare bleeding disorders (RBD), ALN-AS1 for the treatment of acute intermittent porphyria, ALN-PCS for the treatment of hypercholesterolemia, and ALN-TMP for the treatment of hemoglobinopathies. As part of its “Alnylam 5×15TM” strategy, the company expects to have five RNAi therapeutic products for genetically defined diseases in clinical development, including programs in advanced stages, on its own or with a partner by the end of 2015. Alnylam has additional partnered programs in clinical or development stages, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection and ALN-VSP for the treatment of liver cancers. The company’s leadership position on RNAi therapeutics and intellectual property have enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, Cubist, Ascletis, Monsanto, Genzyme, and The Medicines Company. In addition, Alnylam holds a significant equity position in Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam has also formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for applications in biologics manufacturing, including recombinant proteins and monoclonal antibodies. Alnylam’s VaxiRNA™ platform applies RNAi technology to improve the manufacturing processes for vaccines; GlaxoSmithKline is a collaborator in this effort. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 100 peer-reviewed papers, including many in the world’s top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, and Cell. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit www.alnylam.com.

…read more
Source: FULL ARTICLE at DailyFinance